Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Remohí, J.
Right arrow Articles by Pellicer, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Remohí, J.
Right arrow Articles by Pellicer, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 10, No. suppl_2, pp. 84-90, 1995
© 1995 European Society of Human Reproduction and Embryology

Donor-recipient synchronization and the use of gonadotrophin-releasing hormone agonists to avoid the premature luteinizing hormone surge in oocyte donation

J. Remohí1, E. Gallardo, P.P. Guanes, C. Simón and A. Pellicer

Instituto Valenciano de Infertilidad c/o Guardia Civil 23, 46020-Valencia, Spain

Correspondence: 1To whom correspondence should be addressed

Since the introduction of the oocyte donation technique in humans, a number of reports have been published reflecting the success and improvement of this technique. Initially, the most important problems were donor-recipient synchronization at the moment of donation and the premature secretory changes in the endometrium consequent to the spontaneous luteinizinghormone (LH) rise in patients that still showed ovarian function. Today, with the new substitutive hormonal protocols, these two major problems have been solved. The endogenous LH rise can be avoided by administering gonadotrophin-releasing hormone agonists, without any deleterious effects on implantation when they are used in patients with ovarian function. Donor-recipient synchronization is possible because the recipients can remain indefinitely with substitutive therapy until the donation becomes feasible. Here, our experiences with both new strategies are presented.

Key words: donor-recipient synchronization/gonadotrophin-releasing hormone agonists/oocytedonation/premature LH surge


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
L. Dessolle, E. Darai, D. Cornet, R. Rouzier, C. Coutant, J. Mandelbaum, and J.-M. Antoine
Determinants of pregnancy rate in the donor oocyte model: a multivariate analysis of 450 frozen-thawed embryo transfers
Hum. Reprod., December 1, 2009; 24(12): 3082 - 3089.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.